Nova Patents
EP0337713A2

2-Substituted-4-Substituted-1,3-Dioxolanes, Synthesis and use thereof.

Abstract

There is provided novel 2-substituted-4-­substituted-1,3-dioxolanes which are particularly useful as antiviral agents.

EP0337713A2, drawing sheet 1
Sheet 1 of 15

Term

Term ended

Projected expiry passed 11 April 2009, 17.5 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

15 claims: 4 independent, 11 dependent

  1. 1
    A 1,3-dioxolane, derivatives of the general formula (L), the geometric and optical isomers thereof, and mixtures of these isomers:wherein R₁ is selected from the group consisting of hydrogen, an acyl group having 1 to 16 carbon atoms, benzoyl and a benzoyl substituted in any position by at least one halogen, lower alkyl, lower alkoxy, nitro and trifluoromethyl groups;R₂ is a heterocyclic radical selected from wherein R₃ and R₄ are independently selected from the group consisting of hydrogen and lower alkyls;and R₅ is selected from the group consisting of lower alkyl and halogens.
  2. 13
    A method for treating viral infections by administering to an infected host a therapeutically effective amount of a compound of a 2-substituted-4-­substituted-1,3-dioxolane of Formula (L), the geo­metric and optical isomers thereof, and mixtures of these isomers:wherein: R₁ is selected from the group consisting of hydrogen, an acyl group having 1 to 16 carbon atoms, benzoyl and a benzoyl substituted in any position by at least one halogen, lower alkyl, lower alkoxy, nitro and trifluoromethyl groups;R₂ is a heterocyclic radical selected from R₃ and R₄ are independently selected from the group consisting of hydrogen and lower alkyls;and R₅ is selected from the group consisting of lower alkyl and halogens.
  3. 14
    A pharmaceutical composition for treating viral infections comprising an 1,3-dioxolane derivative as claimed in any of Claims 1 to 12 and a pharmaceutically acceptable carrier.
  4. 15
    The use of a 1,3-dioxolane derivative as claimed in any of Claims 1 to 12 in the manufacture of a pharmaceutical composition for treating viral infections.
Independent claims4